Angelini Pharma, an Italian pharmaceutical company, is set to acquire Catalyst Pharmaceuticals in a deal valued at $4.1 billion. This acquisition highlights Angelini's commitment to expanding its portfolio in the rare disease sector.
Catalyst Pharmaceuticals is recognized for its focus on developing treatments for rare diseases, making this acquisition a strategic fit for Angelini as it seeks to enhance its offerings in this niche market.
The transaction reflects ongoing trends in the pharmaceutical industry, where companies are increasingly looking to bolster their capabilities in specialized healthcare areas.